Tanabe/Taisho terminate merger
Executive Summary
Tanabe Seiyaku and Taisho Pharmaceutical terminate proposed merger, citing "differences regarding the most appropriate direction to be pursued post-merger," the companies said Dec. 3 ("The Pink Sheet" Sept. 24, In Brief)...
You may also be interested in...
Tanabe/Taisho integrate operations
Tanabe Seiyaku and Taisho Pharmaceutical will consolidate their pharmaceutical and OTC drug operations under a new holding company, to be headed by Tanabe President Toshio Tanaka. The move appears to take Tanabe out of the pool of potential pharmaceutical acquisition targets in Japan. The businesses will be integrated Oct. 1 and the holding company will be founded on April 1. Combined sales will be approximately $4 bil. in 2002
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.